Skip to main content
Kangmei Pharmaceutical Co.,Ltd logo

Kangmei Pharmaceutical Co.,Ltd — Investor Relations & Filings

Ticker · 600518 ISIN · CNE0000017M1 LEI · 3003006FRNBUUTVKBB50 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,369 across all filing types
Latest filing 2025-04-18 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600518

About Kangmei Pharmaceutical Co.,Ltd

http://www.kangmei.com.cn

Kangmei Pharmaceutical Co.,Ltd. focuses on the research, development, production, and distribution of Traditional Chinese Medicine (TCM). The company manages an integrated industry chain that includes herbal cultivation, standardized processing of decoction pieces, and the manufacturing of patent medicines. Its offerings extend to health supplements, medical devices, and functional foods. A key component of its operations is the management of large-scale TCM trading centers and logistics hubs designed to standardize the trade of medicinal materials. Through its "Internet + Healthcare" initiatives, the company provides digital health management and pharmaceutical supply chain services, catering to medical institutions, retail pharmacies, and individual consumers.

Recent filings

Filing Released Lang Actions
康美药业2024年度独立董事述职报告（骆涛）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2024 by an independent director of the company. It details the director's duties, attendance at board and committee meetings, communication with auditors, oversight of financial reporting, and other governance-related activities during the year. It does not contain financial statements or comprehensive financial performance data typical of an Annual Report (10-K) or Interim Report (IR). It is a detailed management/governance-related report focusing on the director's role and oversight, which aligns with Board/Management Information filings. There is no indication that this is a proxy statement, remuneration report, or regulatory filing. The length and detail confirm it is a substantive report, not a brief announcement or certification. Therefore, the best fit is Board/Management Information (MANG).
2025-04-18 Chinese
康美药业关于续聘会计师事务所的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the proposed reappointment of an accounting firm (audit firm) for the company 康美药业股份有限公司. It details the background, qualifications, and integrity of the accounting firm 中审众环会计师事务所, the audit fees, and the approval process by the audit committee and board of directors. There is no actual audit report or financial statements included, only information about the appointment process and firm credentials. The document is relatively short (2327 characters) and serves as a formal announcement rather than a full audit report or annual report. Therefore, it fits best under the category of Audit Report / Information (AR), which includes standalone audit reports and related information about audit firms and their appointment, excluding full annual reports. FY 2024
2025-04-18 Chinese
康美药业2024年年度报告
Annual Report Classification · 100% confidence The document is titled "康美药业股份有限公司2024 年年度报告" which translates to "Kangmei Pharmaceutical Co., Ltd. 2024 Annual Report." It contains detailed financial data, management discussion and analysis, company overview, financial statements, audit opinions, and other comprehensive information typical of a full annual report. The document length is 15,000 characters, indicating a full report rather than a brief announcement. It includes audited financial results, management analysis, risk disclosures, and detailed segment information. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2024
2025-04-18 Chinese
康美药业第十届监事会2025年度第一次会议决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Kangmei Pharmaceutical Co., Ltd. regarding their first meeting in 2025. It includes voting results on various reports and proposals related to the 2024 fiscal year, such as the 2024 Annual Report, Internal Control Evaluation Report, Profit Distribution Plan, Financial Final Accounts Report, and other related matters. The document states that these reports and proposals will be submitted to the shareholders' meeting for approval and refers readers to the Shanghai Stock Exchange website for the full reports. The document itself is a formal announcement of the Supervisory Board's meeting resolutions and voting outcomes, not the full reports themselves. It is also relatively short (1374 characters) and mainly summarizes decisions and references other documents. Therefore, it fits best into the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially announces the voting results of the Supervisory Board meeting on key company reports and proposals.
2025-04-18 Chinese
康美药业关于公司2024年度日常关联交易执行情况及2025年度日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the execution and forecast of daily related-party transactions for the year 2024 and 2025 by 康美药业股份有限公司 (Kangmei Pharmaceutical Co., Ltd.). It includes extensive tables of transaction amounts, descriptions of related parties, their business scope, and the company's internal procedures for approving these transactions. The document is an official announcement made by the company's board and includes legal disclaimers about the accuracy and completeness of the information. It does not contain financial statements, audit opinions, or earnings highlights, nor is it a transcript or presentation. It is a regulatory announcement about related-party transactions, which is a typical regulatory disclosure in many jurisdictions. Given the nature of the content and the absence of financial statements or management discussion of financial results, this document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-04-18 Chinese
康美药业关于选举董事长、监事会主席、董事会专门委员会委员及聘任高级管理人员、证券事务代表的公告
Board/Management Information Classification · 100% confidence The document is an official announcement from 康美药业股份有限公司 regarding the election of the chairman of the board, chairman of the supervisory board, members of the board's specialized committees, and the appointment of senior management and securities affairs representatives. It details the results of the company's 2025 first extraordinary general meeting and subsequent board meetings, including names, roles, and qualifications of the appointed individuals. There is no financial data, no discussion of financial results, no audit opinions, no legal proceedings, no capital changes, and no voting results from a general meeting. The document is a formal announcement of changes in the company's board and senior management personnel. Therefore, it fits the category of Board/Management Information (MANG). The document length (5524 characters) and content confirm it is not a brief announcement or a report publication notice but a substantive announcement of management changes.
2025-02-17 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.